Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Bellerophon Therapeutics stock opened at $0.01 on Friday. The firm has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 52 week ...

It certainly was a big week — with companies having to raise more than $100 million to make the list. Biotech- and healthcare-related startups led the way — as those companies dominate the list, ...

Verdiva launched with $411 million. Indian drugmaker Anthem Biosciences filed for an IPO worth $397 million. Tenvie Therapeutics emerged with $200 million. Maze Therapeutics files for $115 million ...

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small ...